Edwards Lifesciences Corporation is the global structural heart company. The Company partners with clinicians and researchers and invests in research and development to improve care for those impacted by structural heart disease. Its product categories include Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart. It provides transcatheter heart valve replacement technologies designed for the minimally-invasive replacement of aortic heart valves. TAVR category includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra and the Edwards SAPIEN 3 Ultra RESILIA systems. TMTT category includes the PASCAL Precision transcatheter repair system, EVOQUE tricuspid valve replacement system and Cardioband tricuspid valve reconstruction system. Its INSPIRIS RESILIA aortic valve, offers RESILIA tissue and VFit technology. It is managed in various geographical regions, such as United States, Europe, Japan and Rest of World.

Edwards Lifesciences Corp 프로필



종목 코드 EW

회사 이름Edwards Lifesciences Corp

상장일Mar 27, 2000

CEOZovighian (Bernard J)

직원 수15800

유형Ordinary Share

회계 연도 종료Mar 27

주소One Edwards Way

도시IRVINE

증권 거래소NASDAQ OMX NASDAQ Basic NYSE

국가United States of America

우편 번호92614

전화19492502500

웹사이트https://www.edwards.com

종목 코드 EW

상장일Mar 27, 2000

CEOZovighian (Bernard J)

Edwards Lifesciences Corp의 회사 임원진



이름

이름/직위

직위

주식 보유

변동

Mr. Scott B. Ullem

Chief Financial Officer, Corporate Vice President

284.40K

+2.48%

Ms. Theodora (Doretta) Mistras

Corporate Vice President, Chief Financial Officer

99.92K

Ms. Theodora (Doretta) Mistras

Corporate Vice President, Chief Financial Officer

99.92K

Mr. Steven R. (Steve) Loranger

Independent Director

79.69K

+5.41%

Mr. Steven R. (Steve) Loranger

Independent Director

79.69K

+5.41%

Mr. Daniel J. Lippis

Corporate Vice President - Transcatheter Aortic Valve Replacement

39.29K

Mr. Daniel J. Lippis

Corporate Vice President - Transcatheter Aortic Valve Replacement

39.29K

Mr. Bernard J. Zovighian

Chief Executive Officer, Director

29.80K

-1.07%

Mr. Bernard J. Zovighian

Chief Executive Officer, Director

29.80K

-1.07%

Mr. Daveen Chopra

Corporate Vice President - Transcatheter Mitral and Tricuspid Therapies (TMTT), Surgical Structural Heart (SURG) and Implantable Heart Failure Management (IHFM)

22.22K

-1.79%

이름

이름/직위

직위

주식 보유

변동

Mr. Scott B. Ullem

Chief Financial Officer, Corporate Vice President

284.40K

+2.48%

Ms. Theodora (Doretta) Mistras

Corporate Vice President, Chief Financial Officer

99.92K

Ms. Theodora (Doretta) Mistras

Corporate Vice President, Chief Financial Officer

99.92K

Mr. Steven R. (Steve) Loranger

Independent Director

79.69K

+5.41%

Mr. Steven R. (Steve) Loranger

Independent Director

79.69K

+5.41%

Mr. Daniel J. Lippis

Corporate Vice President - Transcatheter Aortic Valve Replacement

39.29K

자주 묻는 질문

Edwards Lifesciences Corp의 상위 5대 주주는 누구인가요?



Edwards Lifesciences Corp의 상위 5대 주주는 다음과 같습니다: Mr. Scott B. Ullem

Edwards Lifesciences Corp(EW)의 주식을 보유한 기관은 몇 개입니까?



2026Q1 기준으로, Edwards Lifesciences Corp의 주식을 보유한 기관은 총 2620곳이며, 이들이 보유한 주식의 총 가치는 약 539.60M로 전체 발행 주식의 93.71%를 차지합니다. 이는 2025Q4 대비 -12944884.00 증가한 수치입니다.

Edwards Lifesciences Corp의 최대 수익원은 무엇인가요?



2026Q1 기준, Edwards Lifesciences Corp의 Transcatheter Aortic Valve Replacement 부문이 가장 높은 매출을 기록했으며, 금액은 1.26B로 전체 매출의 72.27%를 차지했습니다.